Abstract
Originally identified as a gene specifically induced by IL-9 in a mouse T cell lymphoma, IL-22 is mainly produced by TH1 cells or by activated T cells. Human IL-22, which shares 79% amino acid identity with its mouse orthologue and 25% with IL-10 is encoded by a single copy gene and located on chromosome 12, close to the IFNγ gene, whereas the murine IL-22 gene is located on chromosome 10 and is duplicated in some mouse strains. Structurally, IL-22 appears to be a monomer composed of six alpha helices, whose organization is reminiscent of the helices of the IL-10 dimer. Despite its structural relationship with IL-10, IL-22 exerts completely different activities, acting mainly on non hematopoietic cells, such as epithelial cells from lung and colon, hepatocytes and keratinocytes. IL-22 might therefore be involved in inflammatory processes, at least in liver and skin. IL-22 exerts its activity via a complex formed by IL-10Rβ and IL-22R, associated with Tyk2 and Jak1, respectively. The main signaling pathways triggered by IL-22 involve STAT-1, - 3, -5 and the ERK, JNK and p38 MAPKinases. Beside its transmembrane receptor, IL-22 also binds to a soluble receptor, called IL-22BP. This soluble receptor turns out to be a natural antagonist of IL-22 biological activities at least in vitro.
Keywords: IL-22, inflammation, receptors
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: IL-22 and Its Receptors, New Players in the Inflammatory Network
Volume: 5 Issue: 3
Author(s): Laure Dumoutier and Jean-Christophe Renauld
Affiliation:
Keywords: IL-22, inflammation, receptors
Abstract: Originally identified as a gene specifically induced by IL-9 in a mouse T cell lymphoma, IL-22 is mainly produced by TH1 cells or by activated T cells. Human IL-22, which shares 79% amino acid identity with its mouse orthologue and 25% with IL-10 is encoded by a single copy gene and located on chromosome 12, close to the IFNγ gene, whereas the murine IL-22 gene is located on chromosome 10 and is duplicated in some mouse strains. Structurally, IL-22 appears to be a monomer composed of six alpha helices, whose organization is reminiscent of the helices of the IL-10 dimer. Despite its structural relationship with IL-10, IL-22 exerts completely different activities, acting mainly on non hematopoietic cells, such as epithelial cells from lung and colon, hepatocytes and keratinocytes. IL-22 might therefore be involved in inflammatory processes, at least in liver and skin. IL-22 exerts its activity via a complex formed by IL-10Rβ and IL-22R, associated with Tyk2 and Jak1, respectively. The main signaling pathways triggered by IL-22 involve STAT-1, - 3, -5 and the ERK, JNK and p38 MAPKinases. Beside its transmembrane receptor, IL-22 also binds to a soluble receptor, called IL-22BP. This soluble receptor turns out to be a natural antagonist of IL-22 biological activities at least in vitro.
Export Options
About this article
Cite this article as:
Dumoutier Laure and Renauld Jean-Christophe, IL-22 and Its Receptors, New Players in the Inflammatory Network, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2006; 5 (3) . https://dx.doi.org/10.2174/187152306778017665
DOI https://dx.doi.org/10.2174/187152306778017665 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Surface Plasmon Resonance Imaging (SPRI) Sensor for Cystatin Determination Based on Immobilized Papain
Protein & Peptide Letters Cellular Targets for Anticancer Strategies
Current Drug Targets The Roles of Antimicrobial Peptides in Innate Host Defense
Current Pharmaceutical Design Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Cytokines and Hormones in the Regulation of Hypoxia Inducible Factor-1α (HIF-1α)
Cardiovascular & Hematological Agents in Medicinal Chemistry Protective Effect of Urate Oxidase on Uric Acid Induced-Monocyte Apoptosis
Current Drug Discovery Technologies Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Microwave-assisted Cycloaddition Reactions in Carbo- and Heterocyclic Chemistry
Current Organic Chemistry Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy Molecular Docking and Dynamics Simulation of Vibrio anguillarum Aspartate Semialdehyde Dehydrogenase with Natural Product Caulerpin
Letters in Drug Design & Discovery The Molecular Targets of Antitumor 2-deoxycytidine Analogues
Current Drug Targets Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Ectonucleotidases and Nucleotide/Nucleoside Transporters as Pharmacological Targets for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Patenting the Gene-Hubs of Endoplasmic Reticulum Stress: The Systems Biology Approach
Recent Patents on Biotechnology Back Pain in Children and Adolescents: Etiology, Clinical Approach and Treatment
Current Pediatric Reviews Role of CHK2 Inhibitors in the Cellular Responses to Ionizing Radiation
Mini-Reviews in Medicinal Chemistry